Lindbrook Capital’s Rentokil RTO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$15K Sell
655
-313
-32% -$7.55K ﹤0.01% 1481
2024
Q4
$24.5K Sell
968
-453
-32% -$11.5K ﹤0.01% 1164
2024
Q3
$35.4K Sell
1,421
-78
-5% -$2.31K ﹤0.01% 980
2024
Q2
$44.4K Buy
1,499
+294
+24% +$8.16K ﹤0.01% 847
2024
Q1
$36.3K Buy
1,205
+163
+16% +$4.52K ﹤0.01% 911
2023
Q4
$29.8K Sell
1,042
-270
-21% -$7.93K ﹤0.01% 979
2023
Q3
$48.6K Buy
1,312
+26
+2% +$993 0.01% 703
2023
Q2
$50.2K Buy
1,286
+7
+0.5% +$274 0.01% 724
2023
Q1
$46.7K Buy
1,279
+170
+15% +$5.37K 0.01% 722
2022
Q4
$34.2K Buy
+1,109
New +$34.4K ﹤0.01% 826

Other funds holding RTO

Lindbrook Capital's RTO Position: Q1 2025 in Review

Lindbrook Capital reduced its Rentokil (RTO) stake by 32% in Q1 2025, selling an estimated $7.55K and leaving 655 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

Lindbrook Capital first reported a position in RTO in Q4 2022 and has held it in 10 quarters since. The position peaked at $50.2K in Q2 2023. 210 funds tracked by Wall St. Rank hold RTO as of Q1 2025.

  • Lindbrook Capital held 655 shares of Rentokil worth $15K as of Q1 2025.
  • Lindbrook Capital sold 313 Rentokil shares in Q1 2025, an estimated $7.55K.
  • Rentokil made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1481 holding.
  • Lindbrook Capital first reported a position in Rentokil in Q4 2022 and has held it in 10 quarters since.
  • Lindbrook Capital's Rentokil position peaked at $50.2K in Q2 2023.
  • 210 funds tracked by Wall St. Rank held Rentokil as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.